Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.


Related Content

On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms
ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle
Eliquis Delay Fuels Speculation About Advisory Committee Meeting
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts